Skip Navigation

Japanese Journal of Clinical Oncology 2004 34(6):307-311; doi:10.1093/jjco/hyh055
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Krishna, S. M.
Right arrow Articles by Balaram, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishna, S. M.
Right arrow Articles by Balaram, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Foundation for Promotion of Cancer Research

Serum EBV DNA as a Biomarker in Primary Nasopharyngeal Carcinoma of Indian Origin

Smriti M. Krishna1, Susan James2, Jayasree Kattoor3 and Prabha Balaram4,+

1 Division of Cancer Research, Regional Cancer Center, 2 Department of ENT, Medical College Hospital, Trivandrum, 3 Division of Cytopathology, Regional Cancer Center and 4 Division of Cancer Research, Regional Cancer Center, Kerala, India

Background: Nasopharyngeal carcinoma (NPC) is a unique tumor due to its etiology and endemic distribution. Ethnic and regional factors are found to strongly influence the risk of disease; however, there have been no well-conducted studies on Indian patients. The present study assesses the relationship between Epstein–Barr Virus (EBV) and sporadic Indian NPC and the role of serum EBV DNA in NPC detection.

Methods: Primers directed against non-polymorphic Epstein–Barr nuclear antigen-1 (EBNA-1) gene were used to detect the presence of EBV DNA from fresh tissue and serum in NPC, using PCR.

Results: EBV DNA was detected in 69% of the biopsies and 58% of the serum of the NPC patients. With respect to histology, WHO Type III NPC, WHO Type II tumors and WHO I tumors showed 100%, 72.2% and 33% EBV positivity, respectively. EBV positivity was also observed in 23% (6/26) of benign samples. All biopsies of patients with positive serum samples were positive for EBV DNA.

Conclusion: EBV infection was found in sporadic NPC of South Indian origin, which confirms the etiological role of EBV in NPC. Detection of EBNA-1 in the serum and corresponding tissues of NPC patients suggests that the serum EBV DNA originates from NPC and also indicates the benefit of circulating viral DNA as an early marker in the diagnosis of NPC. Serum DNA-PCR methods can be extrapolated to follow-up studies involving tumor regression or to assess the response to various therapies.

+ For reprints and all correspondence: Prabha Balaram, Associate Professor and Head, Research Division, Regional Cancer Center, Trivandrum 695 011, Kerala, India. E-mail: prabhabalaram{at}yahoo.co.in


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.